Practice Guidelines for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis in an Intensive Care Setting

Zia Hashim, DM¹, Zafar Neyaz, MD¹, Rungmei S.K. Marak, MD¹, Alok Nath, DM¹, Soniya Nityanand, MD, PhD¹, and Naresh K. Tripathy, PhD¹

Abstract
Coronavirus disease-2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a new disease characterized by secondary Aspergillus mold infection in patients with COVID-19. It primarily affects patients with COVID-19 in critical state with acute respiratory distress syndrome, requiring intensive care and mechanical ventilation. CAPA has a higher mortality rate than COVID-19, posing a serious threat to affected individuals. COVID-19 is a potential risk factor for CAPA and has already claimed a massive death toll worldwide since its outbreak in December 2019. Its second wave is currently progressing towards a peak, while the third wave of this devastating pandemic is expected to follow. Therefore, an early and accurate diagnosis of CAPA is of utmost importance for effective clinical management of this highly fatal disease. However, there are no uniform criteria for diagnosing CAPA in an intensive care setting. Therefore, based on a review of existing information and our own experience, we have proposed new criteria in the form of practice guidelines for diagnosing CAPA, focusing on the points relevant for intensivists and pulmonary and critical care physicians. The main highlights of these guidelines include the role of CAPA-appropriate test specimens, clinical risk factors, computed tomography of the thorax, and non-culture-based indirect and direct mycological evidence for diagnosing CAPA in the intensive care unit. These guidelines classify the diagnosis of CAPA into suspected, possible, and probable categories to facilitate clinical decision-making. We hope that these practice guidelines will adequately address the diagnostic challenges of CAPA, providing an easy-to-use and practical algorithm to clinicians for rapid diagnosis and clinical management of the disease.

Keywords
COVID-19-associated pulmonary aspergillosis, diagnosis, practice guidelines, intensive care, clinical risk factors, computed tomography, non-culture-based mycological factors

Introduction
Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection caused by Aspergillus species.¹ It usually occurs in immunocompromised individuals who have neutropenia, hematologic malignancies, acquired or genetic immunodeficiencies, hematopoietic stem cell or solid organ transplantation, and corticosteroid or other immunosuppressive therapies.² Recently, after the outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), IPA has been frequently observed in these otherwise immunocompetent patients. This new entity of the disease has been termed COVID-19-associated pulmonary aspergillosis (CAPA).³–⁵ It mainly affects patients with COVID-19 in critical state with acute respiratory distress syndrome (ARDS), requiring intensive care and mechanical ventilation. Pulmonary lesions and immune dysfunctions caused by SARS-CoV-2 render patients with COVID-19 susceptible to CAPA. The risk of CAPA in patients with COVID-19 increases more after treatment with immunomodulators (eg, tocilizumab) and corticosteroids (eg, prednisolone or dexamethasone) that impairs neutrophil and lymphocyte functions and induces an immunosuppressed state.⁶–⁸ Critical COVID-19 patients with an immunosuppressed state acquire Aspergillus infection from the environment including hospital air, and develop CAPA as schematically shown in Figure 1.

CAPA was initially highlighted through case reports.³–⁵ Subsequent case series⁹–¹⁴ and cohort studies⁶,¹⁵–¹⁹ have reported its frequency as varying from 3% to 35%. CAPA is

¹Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India

Received May 30, 2021. Received revised August 26, 2021. Accepted September 1, 2021.

Corresponding Author:
Naresh Kumar Tripathy, Microbial Hematology Laboratory, Department of Hematology, SGPGIMS, Raebareli Road, Lucknow 226014, India.
Email: nareshtripathy@gmail.com; tripathyn@sgpgi.ac.in.
responsible for >60% mortality in patients with COVID-19.17–19 Thus, it is a frequent and fatal complication in patients with COVID-19 and poses a serious threat. COVID-19 is a potential risk factor for CAPA and has already claimed a massive death toll worldwide since its outbreak in December 2019. Its second wave is currently progressing towards a peak, while the third wave of this devastating pandemic is expected to follow. Therefore, an early and accurate diagnosis of CAPA is of utmost importance for effective clinical management of this highly fatal disease.20–22

The diagnosis of CAPA is challenging for intensivists, and pulmonary and critical care physicians as both IPA and COVID-19 are lower respiratory tract pulmonary infections with overlapping signs and symptoms, and no significant differences in clinical characteristics of patients with COVID-19 versus those with presumed CAPA. There are no uniform criteria for diagnosing CAPA in an intensive care setting, and hence, it is often missed or misdiagnosed in the patients.23–26 Various studies have diagnosed CAPA either by recovering *Aspergillus* species from culture or applying diagnostic algorithms proposed for immunocompromised conditions, influenza-associated pulmonary aspergillosis (IAPA), or other patients in the intensive care unit (ICU) and have reported a widely variable incidence of the disease.6,9–19 These non-CAPA algorithms include the European Organization for Research and Treatment of Cancer and the Mycoses Study Group (EORTC/MSG) criteria,2 Aspergillus ICU (AspICU) criteria,27 modified AspICU criteria,28 IAPA criteria,29 and biomarker–AspICU (BM-AspICU) criteria.30 However, these algorithms do not take account of the unique pathology of CAPA, and CAPA-appropriate specimens for the diagnosis of the disease.

Recently, two algorithms, namely the European Confederation of Medical Mycology, the International Society for Human and Animal Mycology (ECMM/ISHAM) criteria,31 and AspCOVID-19 criteria32 were proposed for the diagnosis of CAPA. However, they are quite rigid and complex for use in routine clinical practice, particularly in ICU/emergency clinics that require a rapid diagnosis. Furthermore, they rely on fungal cultures and do not include the complete profile of fungal biomarkers important for establishing a rapid diagnosis of CAPA (Table 1). In the present study, we aimed to propose clinically practicable diagnostic criteria based on CAPA-appropriate test specimens and diagnostic factors for the rapid detection of CAPA in an intensive care setting.

**CAPA-Appropriate Test Specimens**

An early diagnosis of CAPA is usually hampered by a lack of a consensus on the best (ie, disease-appropriate) specimens for testing in terms of sensitivity and practicability. A lung biopsy is the only specimen to demonstrate a definitive or proven *Aspergillus* infection.2 However, being an invasive procedure, it is not feasible in the majority of CAPA patients due to significant risks associated with their critical illness and hemodynamic instability.25

Conventional blood or serum specimens may be helpful in diagnosing *Aspergillus* infection but they have low sensitivity when used alone because being a nonneutropenic condition, CAPA predominantly has a broncho-invasive *Aspergillus* infection with fungal growth confined mainly to lung tissues during the early phase of the disease.9,12,24,33,34 Therefore, obtaining direct pulmonary specimens is essential, and its rationale is that the deeper the specimen, the higher the diagnostic value for CAPA. Accordingly, bronchoalveolar lavage (BAL), and nonbronchoscopic lavage (NBL) represent CAPA-appropriate specimens for early diagnosis of the disease (Table 2).
| Criteria         | Specimens     | Mycology Tests                  | CAPA Definitions                                                                 | Limitation                                                                 |
|------------------|---------------|--------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| **EORTC/MSG**    | Serum/Plasma  | Microscopy and Culture          | Proven CAPA: Histopathology or culture (+) lung biopsy.                          | These criteria are for immunocompromised patients and not applicable to CAPA. |
| Criteria-2020    | BAL           | GM assay                        | Possible CAPA:                                                                  |                                                                             |
|                  | Bronchial Brush | Aspergillus PCR                 | (i) Host Factors (+)                                                            |                                                                             |
|                  | Sputum        |                                 | (ii) Radiology (+)                                                              |                                                                             |
|                  |               |                                 | (iii) Mycology (-)                                                             |                                                                             |
|                  |               |                                 | Probable CAPA:                                                                 |                                                                             |
|                  |               |                                 | (i) Host Factors (+)                                                            |                                                                             |
|                  |               |                                 | (ii) Radiology (+)                                                             |                                                                             |
|                  |               |                                 | (iii) Mycology (+)                                                             |                                                                             |
| **AspICU Criteria** | Serum | Microscopy and culture          | Proven CAPA: Histopathology or culture (+) lung biopsy.                          | Requires BAL and mycology cultures.                                         |
|                  | BAL           | GM assay                        | Possible CAPA: Putative CAPA:                                                   | No fungal biomarkers and Aspergillus-PCR.                                   |
|                  | TA            |                                 | (i) Aspergillus (+) TA culture                                                  | Originally proposed for critical ICU patients with various conditions.      |
|                  |               |                                 | (ii) Clinical Features (+)                                                      |                                                                             |
|                  |               |                                 | (iii) Radiology (+)                                                            |                                                                             |
|                  |               |                                 | (iv) Mycology (+)                                                              |                                                                             |
| **Modified AspICU Criteria** | Serum | Microscopy and culture          | Proven CAPA: Histopathology or culture (+) lung biopsy.                          | Requires BAL and mycology culture.                                          |
| Criteria²⁸       | BAL           | GM assay                        | Possible CAPA:                                                                  | No Aspergillus-PCR and fungal biomarkers other than GM.                     |
|                  |               |                                 | (i) Clinical Features (+)                                                      | Originally proposed for IAPA                                                |
|                  |               |                                 | (ii) Radiology (+)                                                             |                                                                             |
|                  |               |                                 | (iii) Mycology (+)                                                             |                                                                             |
| **IAPA Criteria** | Serum | Microscopy and culture          | Proven CAPA: Histopathology or culture (+) lung biopsy.                          | Requires BAL and mycology culture.                                          |
| Criteria²⁹       | BAL           | GM assay                        | Possible CAPA:                                                                  | No Aspergillus-PCR and fungal biomarkers other than GM.                     |
|                  | TA            |                                 | (i) Clinical Features (+)                                                      | Originally proposed for IAPA                                                |
|                  | Sputum        |                                 | (ii) Radiology (+)                                                             |                                                                             |
|                  |               |                                 | (iii) Mycology (+)                                                             |                                                                             |
| **BM-AspICU Criteria** | Serum | Microscopy and culture          | Probable CAPA:                                                                  | Requires BAL and mycology culture.                                          |
| Criteria³⁰       | BAL           | GM assay                        | (i) Clinical Features (+)                                                      | No fungal biomarker other than GM and Aspergillus-PCR.                       |
|                  |               |                                 | (ii) Radiology (+)                                                             | Proposed for ICU patients with various conditions                           |
|                  |               |                                 | (iii) ≥2 Mycology (+)                                                          |                                                                             |
|                  |               |                                 | Possible CAPA:                                                                 |                                                                             |
|                  |               |                                 | (i) No ≥1 Radiology sign                                                       |                                                                             |
|                  |               |                                 | (ii) No mycology other than BAL culture (+)                                    |                                                                             |
| **ECMM/ISHAM**   | Serum         | Microscopy and culture          | Proven CAPA: Histopathology or culture (+) lung biopsy.                          | Proposed mainly for research and clinical trials.                           |
| Criteria for CAPA³¹ | BAL    | GM assay                        | Possible CAPA:                                                                  | No fungal biomarker other than GM and Aspergillus-PCR.                       |
|                  | NBL           |                                 | (i) Clinical Features (+)                                                      |                                                                             |
|                  |               |                                 | (ii) Radiology (+)                                                             |                                                                             |
|                  |               |                                 | (iii) BAL/Blood-Mycology (+)                                                   |                                                                             |
|                  |               |                                 | Possible CAPA:                                                                 |                                                                             |
|                  |               |                                 | (i) Clinical Features (+)                                                      |                                                                             |
|                  |               |                                 | (ii) Radiology (+)                                                             |                                                                             |
|                  |               |                                 | (iii) Mycology (+)                                                             |                                                                             |

(continued)
AspCOVID-19

Similar to CAPA, the early diagnosis of CAPA is currently gaining momentum. Recently new approaches, and its application in the diagnostic testing of ventilated patients with CAPA. Thus, once the diagnostic utility of NBL is validated in CAPA, its use can be further extended to diagnose the Aspergillus infection in these conditions.

Although CAPA is predominantly a bronchoinvasive disease, it may progress to be angioinvasive during the advanced stage, leading to appearance of disease-associated fungal biomarkers in the peripheral blood as seen in nonsurviving patients with CAPA. Thus, in line with recent international opinion, the mycological testing of both blood and CAPA-appropriate deep respiratory specimens (ie, BAL or NBL) is essential for optimal diagnostic workup of the disease.

CAPA-Appropriate Diagnostic Factors

The pathogenesis of IPA differs between patients with neutropenia (neutropenic) and those with COVID-19 (nonneutropenic), thereby affecting the clinical presentation, radiological findings, and other diagnostic factors. Patients with CAPA

| Criteria | Specimens | Mycology Tests | CAPA Definitions | Limitation |
|----------|-----------|----------------|------------------|------------|
| AspCOVID-19 criteria<sup>22</sup> | Serum | Microscopy and culture | Probable CAPA: (i) Clinical Features (+) | Requires mycology culture. No Aspergillus-PCR and fungal biomarkers other than GM. |
| AspCOVID-19 criteria<sup>22</sup> | NBL | GM assay | (ii) Radiology (+) | |
| AspCOVID-19 criteria<sup>22</sup> | | | (iii) Mycology (+) | |

Abbreviations: CAPA, COVID-19-associated pulmonary aspergillosis; GM, Galactomannan; NBL, nonbronchoscopic lavage; BAL, bronchoalveolar lavage; PCR, polymerase chain reaction; ECMM/ISHAM, European Confederation of Medical Mycology, the International Society for Human and Animal Mycology; BM-AspICU, biomarker Aspergillus ICU; IAPA, influenza-associated pulmonary aspergillosis; AspICU, Aspergillus ICU; GM-LFA, galactomannan lateral flow assay.

Due to its direct lavage from the lungs, BAL carries negligible microbial contamination from the upper aerodigestive tract and represents the preferred test specimen for the diagnosis of CAPA. The availability of BAL from patients with CAPA is often restricted because bronchoscopy, being an aerosol-generating procedure, is usually avoided for safety concerns to prevent the transmission of SARS-CoV-2 from patients to health care workers through aerosolized viral particles. However, to combat this limitation, new and safe procedures of bronchoscopy using a single-use disposable bronchoscope and closed bronchosampler have been devised to obtain BAL from ventilated patients with CAPA.

NBL, also called mini-BAL, is the next lower respiratory tract specimen of choice for CAPA diagnosis. It can be safely obtained using a closed system by deep bronchial suction without bronchoscopy and has a diagnostic value comparable to that of BAL. The usage of NBL instead of BAL is a new approach, and its application in the diagnostic testing of CAPA is currently gaining momentum. Recently proposed ECMM/ISHAM diagnostic guidelines for CAPA have also recommended the use of NBL. Similar to CAPA, the early diagnosis of Aspergillus infection is challenging in several other nonneutropenic conditions, including IAPA, chronic obstructive pulmonary disease, lung transplant recipients, and critically ill ICU patients.

Thus, in line with recent international opinion, the mycological testing of both blood and CAPA-appropriate deep respiratory specimens (ie, BAL or NBL) is essential for optimal diagnostic workup of the disease.

### Table 1. CAPA-Appropriate Test Specimens and Diagnostic Factors.

| Test Specimens | Clinical Features | Risk Factors | CT Findings | Mycological Evidence |
|----------------|------------------|--------------|-------------|---------------------|
| BAL/NBL        | Ards             | Severe COVID-19 requiring ICU care; and Mechanical ventilation, NIV, HFNC | Nodules or consolidation with cavitary or air crescent changes | BDG assay |
| Heparinized Blood | Respiratory insufficiency despite ventilatory support | Corticosteroid therapy | Consolidation in “reverse halo” or “bird nest” appearance” | Galactomannan assay |
| Plain Blood    | Refractory Fever  | Tocilizumab/Other immunomodulatory therapy | Consolidation in broncho-vascular distribution | Mannoprotein lateral flow assay |
|                | Pleuritic chest pain | Uncontrolled diabetes | Appearance of new consolidation patch | Direct Microscopy |
|                | Dyspnea          | CAD            | Multiple nodular lesions | Asp-PCR |
|                | Hemoptysis       | CKD            | Rounded lung lesion with nonenhancing centre | |
|                |                  | COPD           | Tree-in-bud pattern | |
|                |                  | Cirrhosis, hepatic insufficiency | |
|                |                  | Other (chronic alcohol abuse, chronic diseases, cardiac surgery, etc) | |
|                |                  | Severe Immunodeficiency diseases like AIDS and CGD. | |

Abbreviations: COVID-19, coronavirus disease-2019; CAPA, COVID-19 associated pulmonary aspergillosis; BAL, bronchoalveolar lavage; NBL, nonbronchoscopic lavage; ARDS, acute respiratory distress syndrome; ICU, intensive care Unit; NIV, noninvasive ventilation; HFNC, high-flow nasal cannula; CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; AIDS, acquired immunodeficiency disease syndrome; CGD, chronic granulomatous disease; BDG, 1 to 3-β-D-glucan; Asp-PCR, Aspergillus polymerase chain reaction.
have none of the host factors present in neutropenic or immunosuppressed conditions. Thus, the diagnosis of CAPA is established mainly on the presence of mycological evidence of *Aspergillus* infection, while clinical and radiological features of the disease serve as supporting diagnostic factors. An *Aspergillus*-positive culture is conventionally used as mycological evidence of CAPA. Nevertheless, fungal culture is a time-consuming test with low sensitivity and specificity, and recovery of *Aspergillus* species from the culture of clinical specimens is relatively infrequent. Hence, such diagnostic methods are not appropriate for CAPA, which is a medical emergency critically requiring a rapid diagnosis for effective treatment. In recent years, several biomarkers serving as non-culture-based mycological evidence of fungal infection have been identified, and they may be appropriate for rapidly diagnosing CAPA. Here we discuss these nonculture-based rapid diagnostics, including clinical and radiological factors, fungal biomarkers, direct microscopy, and *Aspergillus* DNA (Table 2).

**Clinical Risk Factors**

Clinical risk factors commonly observed in CAPA include refractory fever, pleural rub, chest pain, hemoptysis, respiratory insufficiency, and acute respiratory distress syndrome. These findings also exist in patients with COVID-19 and thus are of limited value in diagnosing CAPA. In patients with severe COVID-19, ICU care and mechanical ventilation, treatment with corticosteroids or immunomodulators, and presence of comorbidities such as uncontrolled diabetes or chronic diseases of the liver, kidney, and heart may serve as potential risk factors for CAPA. Therefore, it is essential to consider these clinical risk factors in the diagnostic workup of CAPA.

**Radiological Imaging**

Although bedside chest radiography can be easily performed in an ICU setting, to our experience it has low sensitivity for detecting super-added *Aspergillus* infection. Hence, a high-resolution computed tomography (CT) scan should be preferred whenever feasible.

The CT scan is an essential diagnostic tool for detecting pulmonary lesions, and most often serves as the first sign of IPA in patients with neutropenia. However, CAPA is a nonneutropenic condition, and in addition to *Aspergillus* infection, several factors, including SARS-CoV-2 infection, host inflammation, and drug induced toxicity, may be involved in the lung damage. Due to these background lung changes in patients with COVID-19, CT images must be carefully reviewed to detect signs of super-added *Aspergillus* infection. Different CT patterns reported in patients with CAPA include nodules with cavities and dendritic sign, reverse halo sign, nodular consolidation, crazy paving, nodular infiltrations, air-crescent sign, pleural effusion, and some indeterminate and atypical signs. Patients with CAPA usually do not have bilateral and peripheral ground-glass opacities alone, which are typical CT findings of COVID-19. Nevertheless, if present, it may be challenging to detect a superimposed *Aspergillus* infection in COVID-19-infected lungs due to the opacities.

Of 50 patients with suspected CAPA identified at our center, CT scan could be performed only in 15 patients. We observed that the development of nodular lesions (possibly cavitating), abscess formation, new consolidation patch, consolidation with cavitation, and cavitary lesion over the background of COVID-19 lung changes led to a suspicion of fungal infection (Figure 2). These lesions commonly appear as nodules, consolidation, or reverse halo patterns during the early stages of CAPA, and some of these may develop cavitation over the next 1 to 2 weeks (Figure 3). Thus, despite specific overlapping COVID-19-related lung changes, many CT findings raise the possibility of CAPA, prompting further investigation for diagnostic confirmation.

Certain CT findings may reflect occlusion of pulmonary arteries in IPA. Typical vessel occlusion sign (VOS) manifested on CT scan consists of pulmonary nodules surrounded by a halo of ground-glass attenuation (halo sign) or pleura-based wedge-shaped areas of consolidation. Nodules are due to coagulation necrosis, whereas the halo of ground glass is due to surrounding alveolar hemorrhage. Pleura-based consolidation areas correspond to hemorrhagic infarcts. These CT findings should be confirmed by CT pulmonary angiography (CTPA) that provides direct evidence of vessel occlusion by detecting filling defect or interruption of vessels. However, CTPA is only useful to perform if large vessels are involved or dense nodules (>10 mm) are present on a basal CT scan. Detection of VOS by CT/CTPA is helpful in diagnosing angioinvasive pulmonary aspergillosis that occurs almost exclusively in immunocompromised patients with neutropenia. However, this form of IPA is rare in immunocompetent patients including CAPA and we also observed no CT findings of vessel occlusion in our CAPA patients.

**Mycological Evidence**

Non-culture-based mycological evidence of CAPA includes the presence of fungal cell wall antigens and *Aspergillus* hyphae or DNA in clinical specimens. *Aspergillus* cell wall antigen tests serve as indirect biomarkers, while direct microscopy and *Aspergillus* DNA testing serve as direct mycological evidence of the disease. The rate of release of fungal antigens in the extracellular milieu is not uniform and varies with time of infection, type of *Aspergillus* species involved, and other conditions. Accordingly, CAPA is usually diagnosed within an average of 10 days (range: 0-51 days) after the COVID-19 diagnosis. Therefore, it is recommended that mycological testing for suspected CAPA be performed on a weekly or bi-weekly basis. The mycological factors appropriate for the rapid diagnosis of CAPA are mentioned here.

**β-D-Glucan**

1-3-β-D-glucan (BDG) is a conserved polysaccharide abundantly found in the cell wall of most fungi, including...
Figure 2. Representative patterns of chest CT of CAPA patients observed at our institute. (a) multiple small nodules with presence of cavitation in left lung nodule, (b) small nodular lesion left upper lobe with presence of cavitation, (c) consolidation in lingular segment with cavitary changes, (d) cavitary lesion, (e) rounded abscess with air fluid level with presence of pneumothorax, and (f) multiple poorly marginated nodular lesions coalescing to form a consolidation patch. The arrows show the case-specific lung lesions.
Abbreviations: CT, computed tomography; CAPA, COVID-19 associated pulmonary aspergillosis.

Figure 3. The CT chest of a 48-year-old diabetic female with COVID-19 pneumonia, (a) CT images of cranial section showing rounded area of consolidation in the form of reverse halo or bird’s nest appearance (arrows). (b) Section just below the carina shows patchy consolidation patch (arrow). (c, d) Corresponding sections showing development of cavitation at the interval of 3 weeks. Mycological tests of the patients were suggestive of CAPA.
Abbreviations: CT, computed tomography; CAPA, COVID-19 associated pulmonary aspergillosis.
Aspergillus, Candida, and Pneumocystis. The United States Food and Drug Administration (US-FDA) in 2004 has approved serum BDG testing by Fungitell Assay (Associates of Cape Cod, Inc., Falmouth, Massachusetts, USA) as a common biomarker of fungal infections. Since 2008, it has been included as a mycological criterion in EORTC/MSG definitions for the diagnosis of fungal diseases in immunocompromised patients. Although BDG is not specific for Aspergillus infection and serves as a pan-fungal screening test, along with other Aspergillus biomarkers, it may be helpful in the diagnosis of aspergillosis. A few recent studies have investigated BDG in NBL, reporting its promising utility in CAPA diagnosis.15,16

Galactomannan

Galactomannan (GM) is another major polysaccharide of the Aspergillus cell wall, and it is released into body fluids during active hyphal growth of the mold in host tissues. A GM test on serum and BAL is more sensitive than culture and since 2002, it has been included as a mycological criterion in the EORTC/MSG definitions for the diagnosis of IPA in immunocompromised patients. The US-FDA in 2003 approved GM detection using Platelia Aspergillus enzyme immunoassay (EIA) kit (BioRad Laboratories) as an in vitro diagnostic test for Aspergillus infection.2

In CAPA, although BAL is the preferred specimen for GM testing, its availability is unfortunately restricted in these cases. The sensitivity of a GM test in serum is low in CAPA (~20%), and a significant fraction of patients with proven disease have negative GM in serum. Detection of GM in NBL (cut-off >1.2) is considered to be clinically relevant mycological evidence for CAPA, and recent diagnostic guidelines of CAPA, namely ECMM/ISHAM criteria and AspCOVID-19 criteria, have recommended mycological investigations including GM and other biomarkers in NBL. Our laboratory has also observed a comparable GM index in NBL and BAL samples of patients with IPA, supporting the utility of NBL in the diagnosis of CAPA.

Mannoprotein

Mannoprotein (MP) is a glycoprotein of the outermost layer of the Aspergillus cell wall, and it is secreted into the external milieu during active hyphal growth of the mold. It can be detected in serum and BAL by immunochromatographic lateral flow assay using a Conformité Européenne (CE)-marked AspLFD (lateral flow device) kit (OLM Diagnostics). This serves as a point-of-care test offering results within <30 min and requires no specific laboratory setup. The ECMM/ISHAM criteria have recommended MP testing in NBL for the definition of CAPA. The GM antigen test sometimes results in false positivity due to its cross-reactivity with non-Aspergillus fungi or with contaminating GM in β-lactam antibiotics and certain food products. In such cases, this non-GM Aspergillus biomarker may be especially helpful to enhance the diagnostic accuracy of CAPA.

Direct Microscopy

Direct microscopy of CAPA-appropriate clinical specimens is the most straightforward and rapid method for detecting Aspergillus and other fungal infections based on their distinctive morphological characteristics. It allows the detection of fungal elements before the growth of fungal cells is apparent in culture. In addition, unlike cultures, direct microscopy excludes the possibility of environmental contamination by airborne fungi. If the specimen has a sufficient number of fungal elements, microscopy may offer a presumptive or even definitive diagnosis within 2 to 3 h of the specimen collection and can thus provide enough information to intensive care physicians for prompt initiation of anti-fungal therapy. The traditional potassium hydroxide (KOH) wet mount method of microscopy has low sensitivity (50% maximum).6 The combination of KOH with Calcofluor or Blankophor (optical brighteners) and subsequent examination by fluorescence microscope enhances the sensitivity of direct microscopy. Therefore, direct fluorescent microscopy of BAL/NBL/blood using optical brighteners may be useful for the optimal diagnostic yield of Aspergillus infection in CAPA (Figure 4).

Aspergillus DNA

Detection of the Aspergillus DNA by polymerase chain reaction (PCR) (Asp-PCR) is a rapid and sensitive (>90%) mycological test, offering direct evidence of the presence of Aspergillus species in clinical specimens. After its inclusion as mycological evidence in recent EORTC/MSG criteria, cultures with low sensitivity and long turnaround time are being consistently replaced by the Asp-PCR. The identification of Aspergillus DNA in culture-negative clinical samples further establishes the diagnostic superiority of Asp-PCR over mycological culture and even microscopy.69–72 The advent of multiplex Asp-PCR has further improved the diagnostic value of Aspergillus DNA testing. It performs a quantitative analysis of the DNA of involved Aspergillus species (A. flavus, A. terreus, and A. niger) to offer an etiological diagnosis of the disease.73,74 However, as with other biomarkers, the detection of Aspergillus DNA in the bloodstream of nonneutropenic patients is low; hence, PCR in respiratory specimens is preferred for enhanced sensitivity.75,76 Although evidence is scarce, available studies exhibit the superiority of Asp-PCR in NBL over blood in CAPA diagnosis. The ECMM/ISHAM criteria for the definition of CAPA have also recommended NBL for Asp-PCR.

Practice Guidelines for the Diagnosis of CAPA

A few months before the outbreak of the COVID-19 pandemic, we established the Microbial Hematology Laboratory at our institute for diagnosing invasive fungal diseases in patients...
with hematological malignancies. The laboratory has GM and MP testing in serum, BAL, and NBL in place, while BDG assay and Asp-PCR are currently being established. Direct microscopy and fungal cultures of blood and respiratory specimens are routine microbiological investigations at our institute. We presumed that diagnosis of alarmingly increasing CAPA cases could be improved and expedited for clinical care using these non-culture-based mycological assays and CAPA-appropriate specimens (ie, BAL, NBL). Therefore, based on the survey of existing diagnostic guidelines and our own experience, we have proposed new criteria for practically easy and rapid diagnosis of CAPA in an intensive care setting. We have named these criteria practice guidelines.

Although the presence of clinical and radiological factors is indicative of an invasive disease, it is difficult to distinguish CAPA from COVID-19 without mycological evidence. In the intensive care setting and routine clinical practice, a definitive or proven diagnosis of CAPA is almost impossible to make due to the lack of lung biopsy. Therefore, to facilitate easy clinical decision-making, our practice guidelines have classified the diagnosis of CAPA into suspected, possible, and probable categories based on clinical and radiological factors, and non-culture-based mycological biomarkers of the disease (Figure 5).

**Suspected CAPA**

We have defined a suspected CAPA as (i) presence of clinical risk factors, and (ii) abnormal CT findings. The clinical risk factors and typical CT patterns indicative of CAPA are the same as described above in the section on diagnostic factors of the disease.

Since this category lacks mycological evidence, the suspected CAPA needs to be upgraded to a possible or probable level by additional investigations for considering antifungal treatment.

**Possible CAPA**

A possible CAPA is defined as suspected CAPA (ie, presence of clinical risk factors and abnormal CT findings) with a positive GM or MP in BAL, NBL, or serum as mycological evidence of the *Aspergillus* infection. In addition, if CT scanning of a patient is deemed unfeasible, the positivity of GM or MP along with the presence of clinical risk factors may also be considered to indicate possible CAPA.

If the mycological biomarker does not test positive in a patient suspected to have CAPA, it would be essential to repeat the test in a second sample drawn after an interval of 24 to 48 h to confirm the result. In settings where BDG, GM, and MP tests are possible, it would be optimal to test any two of these biomarkers at regular intervals for maximizing the timely diagnosis of possible CAPA.

Since possible CAPA represents an intermediate certainty of the disease and includes mycological evidence of *Aspergillus* infection, we can consider it for empirical antifungal treatment. Concurrently, direct mycological evidence, ie, direct microscopy or Asp-PCR, is attempted to upgrade the diagnosis of possible CAPA to a probable level.

**Probable CAPA**

Probable CAPA represents a high certainty of CAPA diagnosis. Its definition includes (i) presence of clinical risk factors, (ii) abnormal CT findings, (iii) positivity of GM or MP biomarker in BAL, NBL, or serum, and (iv) direct microscopy or Asp-PCR (preferably multiplex) detecting *Aspergillus* species in BAL, NBL, or blood samples. The diagnosis of probable CAPA is sufficient to initiate targeted antifungal treatment.

We recommend that testing of all the three proposed fungal biomarkers (ie, BDG, GM, and MP), direct microscopy, and Asp-PCR be performed to improve the diagnostic yield and exclude fungal infections other than *Aspergillus*. When...
resources are limited and the tests have to be applied selectively, the combination of Asp-PCR and GM assay is preferred to obtain the greatest level of diagnostic confidence.77,78

Distinction Between CAPA and Aspergillus Colonization

Aspergillus can cause several forms of pulmonary diseases, ranging from colonization to invasive aspergillosis depending upon the pulmonary and immune functions of the host. Colonization is defined as the isolation of Aspergillus or its DNA from a respiratory sample without radiological and clinical findings of an invasive infection.1,72 Distinguishing benign airway colonization from invasive Aspergillus infection has been challenging because Aspergillus conidia are common inhabitants of our airways and do not always cause an invasive disease. Clinical and radiological findings of CAPA not only support the diagnosis but also indicative of an invasive fungal disease.49,54 Similarly certain fungal biomarkers such as GM and MP are signals of active hyphal growth of the Aspergillus in host tissues and show the presence of fungal infection.61,64 Detection of Aspergillus in a respiratory test specimen by direct microscopy or Asp-PCR alone (ie, in the absence of clinical and radiological features or GM and MP biomarkers of the disease) may reflect colonization rather than infection and has limited diagnostic value.79,80 Therefore, it is always important to define the diagnosis of CAPA taking clinical and radiological features, and fungal biomarkers of the disease into consideration to exclude the possibility of Aspergillus colonization and avoid unnecessary antifungal treatment and unwanted toxicity to patients.

Conclusion & Perspectives

Patients with severe COVID-19 are at high risk of CAPA due to immunosuppression caused by SARS-CoV-2 infection and certain medications. Definitions of CAPA available in the literature are complex and not suitable for intensive care settings, where early therapy is essential to save patients.24,31 Our practice guidelines, which include comprehensive diagnostic interventions comprising fungal biomarkers (BDG, GM, and MP), direct microscopy, and Asp-PCR, are meant explicitly for intensive care application. To the best of our knowledge, these guidelines represent the first purely nonculture-based criteria providing an easy-to-use and practicable algorithm for rapid diagnosis of CAPA to provide urgent clinical management of the disease. The outbreak of COVID-19 has led to the establishment of PCR in almost all major hospitals, and microscopy is a routine microbiology investigation. Other diagnostics such as BDG, GM, and MP included in our guidelines are commercial
kit-based easy-to-perform tests producing rapid results and need no specific laboratory infrastructure. Even if the Asp-PCR is not yet established in some limited-resource laboratories, possible CAPA can be identified or ruled out using simple mycological tests like BDG, GM, and MP in BAL, NBL, or serum. Thus, our practice guidelines could serve as widely applicable criteria for a precise and rapid diagnosis of CAPA. Although we have not included mycological culture in our diagnostic criteria owing to their low sensitivity and long turnaround time, it is a significant pillar of fungal diagnostics and therapeutics. Therefore, once a CAPA diagnosis is achieved, the culture of the Aspergillus-positive specimen would be essential for identification of the involved Aspergillus species and antifungal susceptibility testing for individualized therapy.1,2 Although several studies have reported the utility of NBL and other respiratory specimens in the diagnosis of CAPA,15,21,43,45 validation of Aspergillus infection by histopathology of lung autopsy of patients with CAPA will be helpful for authentication and routine application of these guidelines. Thus, we believe that establishing a consensus definition of CAPA requires more efforts, particularly those directed towards the performance of existing biomarkers and identification of more sensitive new biomarkers for the disease.

Acknowledgments
The authors acknowledge the contribution of Dr Prasant Areekkara: MD, DNB; Department of Pulmonary Medicine, SGPGIMS, Lucknow, for reviewing and editing this manuscript.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Lucknow-226014, India (Grant no. PGI/DIR/RC/662/2020).

Ethical Approval
Not applicable, because this article does not contain any studies with human or animal subjects.

ORCID iDs
Naresh K. Tripathy, PhD; https://orcid.org/0000-0002-2621-802X

Supplemental Material
Supplemental material for this article is available online

References
1. Ledoux MP, Guffroy B, Nivoix Y, Simand C, Herbrecht R. Invasive pulmonary aspergillosis. Semin Respir Crit Care Med. 2020;41(1):80-98. https://doi.org/10.1055/s-0039-3401990
2. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367-1376. https://doi.org/10.1093/cid/ciz1008
3. Koehler P, Cornel OA, Bottiger BW, et al. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020;63(6):528-534. https://doi.org/10.1111/myc.13096
4. van Arkel ALE, Rijpstra TA, Belderbos HNA, et al. COVID-19-associated pulmonary aspergillosis. Am J Respir Crit Care Med. 2020;202(1):132-135. https://doi.org/10.1164/rccm.202004-1038LE
5. Santana MF, Pivoto G, Alexandre MAA, et al. Confirmed invasive pulmonary aspergillosis and COVID-19: the value of postmortem findings to support antemortem management. Rev Soc Bras Med Trop. 2020;53:e20200401. https://doi.org/10.1590/0037-8682-0401-2020
6. Dupont D, Menotti J, Ture J, et al. Pulmonary aspergillosis in critically ill patients with coronavirus disease 2019 (COVID-19). Med Mycol. 2021;59(1):110-114. https://doi.org/10.1093/mmymya/a078
7. Ng TT, Robson GD, Denning DW. Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology. 1994;140(9):2475-2479. https://doi.org/10.1099/13500872-140-9-2475
8. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, HLH Across Speciality Collaboration UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
9. Machado M, Valerio M, Alvarez-Uria A, et al. Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity. Mycoses. 2021;64(2):132-143. https://doi.org/10.1111/myc.13213
10. Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020;24(1):299. https://doi.org/10.1186/s13054-020-03046-7
11. Alainio A, Delliere S, Fodil S, Bretagne S, Megarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med. 2020;8(6):e48-e49. https://doi.org/10.1016/S2213-2600(20)30237-X
12. Rutsaert L, Steinfort N, Van Hunsel T, et al. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care. 2020;10(1):71. https://doi.org/10.1186/s13613-020-03068-4
13. Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1065
14. Meijer EFJ, Dofferhoff ASM, Hoiting O, Meis JF. COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series. Mycoses. 2021;64(4):457-464. https://doi.org/10.1111/myc.13254
15. Borman AM, Palmer MD, Fraser M, et al. COVID-19-Associated invasive aspergillosis: data from the UK national mycology reference laboratory. J Clin Microbiol. 2020;59(1). https://doi.org/10.1128/JCM.02136-20
16. White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis. 2020. https://doi.org/10.1093/cid/ciaa1298
17. Salmanton-Garcia J, Sprute R, Stemler J, et al. COVID-19-Associated pulmonary aspergillosis, march-August 2020. *Emerg Infect Dis.* 2021;27(4):1077-1086. https://doi.org/10.3201/eid2704.204895
18. Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan. *Mycoses.* 2020;63(8):766-770. https://doi.org/10.1111/myc.13135
19. Pintado MV, Camiró-Zuniga A, Soto MA, et al. COVID-19-associated invasive pulmonary aspergillosis in a tertiary care center in Mexico City. *Med Mycol.* 2021. https://doi.org/10.1093/mmy/m yab009
20. Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? *J Microbiol Immunol Infect.* 2020;53(4):505-512. https://doi.org/10.1016/j.jmi.2020.05.013
21. White PL, Dhillon R, Hughes H, Wise MP, Backx M. COVID-19 and fungal infection: the need for a strategic approach. *Lancet Microbe.* 2020;1(5):e196. https://doi.org/10.1016/S2666-5247(20)30127-0
22. Nestler M, Godbout E, Lee K, et al. Fungal superinfection in patients with COVID-19: role of antifungal stewardship? *Am J Infect Control.* 2021;49(2):279-280. https://doi.org/10.1016/j.ajic.2020.11.015
23. Hoegnig M. Invasive fungal disease complicating COVID-19: when it rains it pours. *Clin Infect Dis.* 2020. https://doi.org/10.1093/cid/ciaa1342
24. Verweij PE, Gangneux JP, Bassetti M, et al. Diagnosing COVID-19-associated pulmonary aspergillosis. *Lancet Microbe.* 2020;1(2):e53-e55. https://doi.org/10.1016/S2666-5247(20)300115
25. Mohamed A, Rogers TR, Talento AF. COVID-19 Associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges. *J Fungi.* 2020;6(3):115. https://doi.org/10.3390/jof6030115
26. Iri GRT, Cornely OA, Pappas PG, et al. Invasive aspergillosis as an under-recognized superinfection in COVID-19. *Open Forum Infect Dis.* 2020;7(7):ofaa242. https://doi.org/10.1093/ofid/ofaa242
27. Blot SI, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. *Am J Respir Crit Care Med.* 2012;186(1):56-64. https://doi.org/10.1164/rccm.201111-1978OC
28. Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. *Lancet Respir Med.* 2018;6(10):782-792. https://doi.org/10.1016/S2213-2600(18)30274-1
29. Verweij PE, Rijnders BJA, Bruggemann RJM, et al. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. *Intensive Care Med.* 2020;46(8):1524-1535. https://doi.org/10.1007/s00134-020-06091-6
30. Hamam J, Navellou JC, Bellanger AP, et al. New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU. *Ann Intensive Care.* 2021;11(1):41. https://doi.org/10.1186/s13631-021-00827-3
31. Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECM/ISHAM consensus criteria for research and clinical guidance. *Lancet Infect Dis.* 2020. https://doi.org/10.1016/S1473-3099(20)30847-1
32. Lahmer T, Kriescher S, Herner A, et al. Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: results from the prospective AspCOVID-19 study. *PLoS One.* 2021;16(3):e0238825. https://doi.org/10.1371/journal.pone.0238825
33. Lamoth F, Lewis RE, Walsh TJ, Kontoyiannis DP. Navigating the uncertainties of COVID-19 associated aspergillosis (CAPA): a comparison with influenza associated aspergillosis (IAPA). *J Infect Dis.* 2021. https://doi.org/10.1093/infdis/jiab163
34. Vandevonde KL, Blot SI, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. *Crit Care.* 2006;10(1):R31. https://doi.org/10.1186/cc4823
35. Wu Z, Wang L, Tan L, Wu J, Chen Z, Hu M. Diagnostic value of galactomannan in serum and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in non-neutropenic patients. *Diagn Microbiol Infect Dis.* 2021;99(4):115274. https://doi.org/10.1016/j.diagmicrobio.2020.115274
36. Wahidi MM, Shojaee S, Lamb CR, et al. The Use of bronchoscopy during the coronavirus disease 2019 pandemic: CHEST/AAABIP guideline and expert panel report. *Chest.* 2020;158(3):1268-1281. https://doi.org/10.1016/j.chest.2020.04.036
37. Luo F, Darwiche K, Singh S, et al. Performing bronchoscopy in times of the COVID-19 pandemic: practice statement from an international expert panel. *Respiration.* 2020;99(5):417-422. https://doi.org/10.1159/000507898
38. Singh S, Shah PL. Safe and efficient practice of bronchoscopy sampling from mechanically ventilated patients: a structured evaluation of the ambu bronchoscopar-ascope 4 integrated system. *Respiration.* 2021;100(1):27-33. https://doi.org/10.1159/000323176
39. Tasbakan MS, Gurgun A, Basoglu OK, Ekren PK, Pulkuçu H, Bacakoglu F. Comparison of bronchoalveolar lavage and mini-bronchoalveolar lavage in the diagnosis of pneumonia in immuno-compromised patients. *Respiration.* 2011;81(3):229-235. https://doi.org/10.1159/000323176
40. Bonvento BV, Rooney JA, Columb MO, McGrath BA, Bentley AM, Felton TW. Non-directed bronchial lavage is a safe method for sampling the respiratory tract in critically ill patient. *J Intensive Care Soc.* 2019;20(3):237-241. https://doi.org/10.1177/0004363019855775
41. Van Biesen S, Kwa D, Bosman RJ, Juffermans NP. Detection of invasive pulmonary aspergillosis in COVID-19 with Non-directed bronchoalveolar lavage. *Am J Respir Crit Care Med.* 2020. https://doi.org/10.1164/rccm.202005-2018LE
42. Alhazzani W, Moller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Crit Care Med.* 2020;48(6):e440-e469. https://doi.org/10.1097/CCM.0000000000004363
43. Armstrong-James D, Youngs J, Bicanic T, et al. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. *Eur Respir J.* 2020;56(4). https://doi.org/10.1183/13993003.02554-2020
44. Rickert V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. *Clin Infect Dis.* 2007;44(8):1078-1083. https://doi.org/10.1086/512812
45. Guinea J, Bouza E. Current challenges in the microbiological diagnosis of invasive aspergillosis. *Mycopathologia.* 2014;178(5-6):403-416. https://doi.org/10.1007/s11046-014-9763-3
immunocompromised people. *Cochrane Database Syst Rev*. 2019;9:CD009551. https://doi.org/10.1002/14651858.CD009551.pub4

77. Barnes RA, Stocking K, Bowden S, Poynton MH, White PL. Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway. *J Infect*. 2013;67-(3):206-214. https://doi.org/10.1016/j.jinf.2013.04.020

78. Alanio A, Menotti J, Gits-Muselli M, et al. Circulating *Aspergillus* fumigatus DNA is quantitatively correlated to galactomannan in Serum. *Front Microbiol*. 2017;8:2040. https://doi.org/10.3389/fmicb.2017.02040

79. Gago S, Denning DW, Bowyer P. Pathophysiological aspects of *Aspergillus* colonization in disease. *Med Mycol*. 2019;57-(Supplement-2):S219-S227. https://doi.org/10.1093/mmy/mmy076

80. Pemán J, Ruiz-Gaitánb A, García-Vidal C, et al. Fungal co-infection in COVID-19 patients: should we be concerned. *Rev Iberoam Micol*. 2020;37(2):41-46. https://doi.org/10.1016/j.riam.2020.07.001

81. Lee H, Oh J, Sung GH, et al. Multilaboratory evaluation of the MALDI-TOF mass spectrometry system, MicroIDSysElite, for the identification of medically important filamentous fungi. *Mycopathologia*. 2021;186(1):15-26. https://doi.org/10.1007/s11046-020-00507-z

82. Li Y, Wang H, Zhao YP, Xu YC, Hsueh PR. Antifungal susceptibility of clinical isolates of 25 genetically confirmed *Aspergillus* species collected from Taiwan and Mainland China. *J Microbiol Immunol Infect*. 2020;53(1):125-132. https://doi.org/10.1016/j.jmii.2018.04.003